Abstracts tagged "infection and rituximab"

Abstract Number: 236 • 2018 ACR/ARHP Annual Meeting
Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab
Joana Caetano¹, Frederico Batista¹ and Jose Delgado Alves^2,3, ¹Department of Medicine IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal, ²CEDOC/NOVA Medical School, Lisbon, Portugal, ³Department of Medicina IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal
Background/Purpose: Rituximab (RTX) is an effective immunosuppressive therapy for many autoimmune diseases. Secondary hypogammaglobulinemia (hypoIg) can occur mainly after repeated cycles of RTX. The risk…
Abstract Number: 1789 • 2015 ACR/ARHP Annual Meeting
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Eoghan M. McCarthy^1,2, Emily Sutton³, David A. Isenberg⁴, Anisur Rahman⁴, Benjamin Rhodes⁵, Peter Hewins⁶, Neil J McHugh⁷, Ben Parker⁸, Bridget Griffiths⁹, Peter Lanyon¹⁰, Edward M. Vital¹¹, Lee-Suan Teh¹², Mohammed Akil¹³, Hazem Youssef¹⁴, David P. D'Cruz¹⁵, Munther Khamashta¹⁶, Nicola Erb¹⁷, David Jayne¹⁸, Christopher J. Edwards¹⁹, Athiveer Prabu²⁰, Michael Batley²¹, Nagui Gendi²², Bhaskar Dasgupta^23,24, Richard J. Stratton²⁵, Chee-Seng Yee²⁶, Asad Zoma²⁷, Caroline Gordon²⁸, Antoni Chan²⁹, Steven Young Min³⁰, Shirish Dubey³¹, Jon King³², Denise De Lord³³, Edmond O'Riordan³⁴, Rachel Jeffery³⁵, Waji Hassan³⁶, Marian Regan³⁷ and Ian N. Bruce³⁸, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ²The University of Manchester, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Mmanchester, United Kingdom, ³University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ⁴Centre for Rheumatology Research, University College London, London, England, ⁵Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁶Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁷Rheumatology, Bath Institute of Rheumatic Diseases, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁹Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁰Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹²Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom, ¹³Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, ¹⁴Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, ¹⁵Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ¹⁶Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ¹⁷Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ¹⁸Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom, ¹⁹University Hospital Southampton, Southampton, United Kingdom, ²⁰Worcester Royal Hospital, Worcester, Worcester, United Kingdom, ²¹Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom, ²²Rheumatology, Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, ²³Southend University Hospital, Southend, United Kingdom, ²⁴Rheumatology, Southend University Hospital, Essex, United Kingdom, ²⁵Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ²⁶Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ²⁷Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²⁸Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²⁹Rheumatology, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ³⁰Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom, ³¹Rheumatology, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³²Rheumatology, Derriford Hospital, Plymouth, United Kingdom, ³³Rheumatology, Queen Elizabeth the Queen Mother Hospital, East Kent, United Kingdom, ³⁴Renal Medicine, Salford Royal Foundation Trust, Manchester, United Kingdom, ³⁵Rheumatology, Northampton General Hospital, Northampton, United Kingdom, ³⁶Rheumatology, University Hospitals of Leicester, Leicester, United Kingdom, ³⁷Rheumatology, Royal Derby Hospital, Derby, United Kingdom, ³⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom
Background/Purpose: SLE is associated with a significantly increased risk of infection. Both disease activity and the medications required to control disease are contributory factors. Rituximab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].